Latest News

While we enjoy watching the progress our portfolio companies make, we appreciate this does not come easily and requires large measures of expertise, intuition, ingenuity and perseverance. This understanding increases our satisfaction in bringing you news of their accomplishments.

Use the filters above to refine results
7th September 2017

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)

29th August 2017

BOSULIF 1L Regulatory Submissions Acceptance

18th August 2017

Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin)

10th August 2017

Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly

3rd August 2017

Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity

2nd August 2017

Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing

25th July 2017

VenatoRx Raises $42 Million Series B: Versant, Abingworth, Foresite back industry‐leading antibiotics developer

24th July 2017

eFFECTOR Therapeutics Completes $38.6 Million Series C Financing

19th July 2017

Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of Directors

18th July 2017

Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections

30th June 2017

BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

23rd June 2017

GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe

22nd June 2017

Proteon Therapeutics Announces $22.0 Million Private Placement

20th June 2017

eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer

12th June 2017

Sientra to Acquire Miramar Labs®

5th June 2017

Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer

9th May 2017

Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells

4th May 2017

CRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations

3rd May 2017

GammaDelta Therapeutics expands management team led by Paolo Paoletti as CEO

27th April 2017

Avedro Announces $42 Million in Funding to Support Commercial Expansion and Pipeline Development

27th April 2017

Verona Pharma Announces Pricing of Global Offerin

24th April 2017

Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting

20th April 2017

Lombard Medical Appoints New CEO

4th April 2017

Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial

31st March 2017

Dynex Technologies Acquired By Telegraph Hill Partners

30th March 2017

Avillion signs Clinical Co-Development Agreement with Merck to Advance Anti IL-17 A/F Nanobody® in Psoriasis

27th March 2017

Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne

22nd March 2017

Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554

21st March 2017

SutroVax Announces Closing of $64M via Series B Financing

16th March 2017

Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial

22nd February 2017

Verona Pharma Commences further RPL554 Phase 2a Clinical Trial

21st February 2017

GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

18th January 2017

Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study